疏血通注射液联合尿激酶对急性心肌梗死进行静脉溶栓的临床观察

Clinical Observation on Urokinase Combined with Shuxuetong Injection for Acute Myocardial Infarction

目的观察疏血通注射液联合尿激酶在急性心肌梗死进行静脉溶栓的疗效。方法选择50例急性ST段抬高型心肌梗死患者,随机分为对照组与治疗组,各25例。两组据病情常规给予阿司匹林、氯吡格雷、美托洛尔、辛伐他汀、硝酸甘油、低分子肝素、胺碘酮等治疗。对照组在常规治疗基础上加用尿激酶,治疗组在对照组基础上加用疏血通注射液静脉溶栓治疗。观察两组冠状动脉再通率。结果治疗组冠状动脉再通率为80%,高于对照组的64%(P<0.05);凝血指标纤维蛋白原较对照组显著降低(P<0.05),出血率及病死率两组比较无统计学意义(P>0.05)。结论疏血通注射液联合尿激酶对急性心肌梗死的静脉溶栓治疗安全有效,能增加冠状动脉的再通率。

Objective To study the efficacy of Shuxuetong injection combined with urokinase for acute myocardial infarction.Methods Fifty patients（pts） with acute ST-segment elevation myocardial infarction were randomly divided into control group（n=25） and combined treatment group（n=25）.All pts were routinely given aspirin,clopidogrel,metoprolol,simvastatin,nitroglycerin,low molecular heparin,amiodarone.Urokinase was used in control group on the basis of conventional therapy.Shuxuetong injection with urokinase were used in combined treatment group.Results The recanalization rate of coronary artery was 80% in combined treatment group,which was significantly higher than that in control group（64%,P〈0.05）.Fibrinogen were significant difference（P〈0.05）,while bleeding rate and mortality was no significant difference in two groups（P〉0.05）.Conclusion Shuxuetong injection combined with urokinase for treatment of acute myocardial infarction was safe and effective.